Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 12/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.41 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.41 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133690 | 0.87 | CAPN1 (0.52) | CAPN1L3MBTL1ITGB1ITGA4 | |
| SCHEMBL20028628 | 0.87 | CAPN1 (0.52) | CAPN1L3MBTL1ITGB1ITGA4 | |
| SCHEMBL22897251 | 0.85 | CAPN1 (0.47) | CAPN1L3MBTL1ITGB1ITGA4 | |
| SCHEMBL22897206 | 0.85 | HPGDS (0.50) | HPGDSCAPN1CTSLL3MBTL1HSPA1A | |
| SCHEMBL22897249 | 0.84 | CAPN1 (0.48) | CAPN1L3MBTL1 | |
| SCHEMBL22896718 | 0.82 | ALDH1A1 (0.52) | CAPN1CTSLL3MBTL1ITGB1ITGA4 | |
| SCHEMBL22896423 | 0.82 | CAPN1 (0.49) | CAPN1 | |
| SCHEMBL22896368 | 0.82 | CAPN1 (0.49) | CAPN1 | |
| SCHEMBL21854203 | 0.81 | CAPN1 (0.46) | CAPN1CTSLL3MBTL1ITGB1ITGA4 | |
| SCHEMBL20027561 | 0.81 | CAPN1 (0.46) | CAPN1CTSLL3MBTL1ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | HPGDS 1604/4885CAPN1 3/4885CTSL 234/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | HPGDS 1339/4885CAPN1 4/4885CTSL 242/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | HPGDS 1604/4885CAPN1 3/4885CTSL 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.